|
|
|
|
Vol. 62, Issue 2, 265-271, August 2002
Istituto di Cibernetica e Biofisica, Consiglio Nazionale delle
Ricerche, Genova, Italy (A.L., A.A., S.T., P.G., M.P.); Dipartimento
Farmacobiologico (A.L., S.P., A.D.L., D.C.C.) and Dipartimento
Farmacochimico (G.C., G.F., F.L.), Sezione di Farmacologia,
Università di Bari, Bari, Italy; and Dipartimento di Scienze del
Farmaco, Università di Chieti, Chieti, Italy (P.T.)
CLC channels are a gene family of Cl
channels that
serve a variety of functions, several of which are involved in genetic diseases. Few specific ligands of CLC channels are known that could be
useful as pharmacological tools or potential drugs. We synthesized
various derivatives of 2-(p-chlorophenoxy)propionic acid, the S(
)-enantiomer of which is a specific
blocker of the muscle channel CLC-1. In particular, compounds with
different alkyl or phenoxy-alkyl groups on the chiral center, isosteres of the oxygen in the aryloxy moiety, or bioisosteres of the carboxy function were prepared. We found that compounds containing a phenoxy and a phenoxy-alkyl group on the chiral center (bis-phenoxy
derivatives) specifically inhibited renal CLC-K channels from the
extracellular side with an affinity in the 150-µM range and with
almost no effect on other CLC channels when applied from the outside.
Surprisingly, the same substances inhibited CLC-1 from the
intracellular side in a voltage-dependent manner with an apparent
KD of <5 µM at
140 mV, thus being the
most potent blockers of a CLC channel known so far. Although the
chlorine atom in para- position of the second phenoxy
group was essential for inhibition of CLC-K channels from the outside,
it could be substituted by a methoxy group without changing the potency
of block for CLC-1 from the inside. These newly identified substances
provide powerful tools for studying the structure-function relationship
and the physiological role of CLC channels and may represent a starting
point for the development of useful drugs targeting CLC-K channels.
This article has been cited by other articles:
![]() |
A. Liantonio, A. Picollo, G. Carbonara, G. Fracchiolla, P. Tortorella, F. Loiodice, A. Laghezza, E. Babini, G. Zifarelli, M. Pusch, et al. Molecular switch for CLC-K Cl- channel block/activation: Optimal pharmacophoric requirements towards high-affinity ligands PNAS, January 29, 2008; 105(4): 1369 - 1373. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Liantonio, A. Picollo, E. Babini, G. Carbonara, G. Fracchiolla, F. Loiodice, V. Tortorella, M. Pusch, and D. C. Camerino Activation and Inhibition of Kidney CLC-K Chloride Channels by Fenamates Mol. Pharmacol., January 1, 2006; 69(1): 165 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Pusch, G Zifarelli, A. R Murgia, A Picollo, and E Babini Channel or transporter? The CLC saga continues Exp Physiol, January 1, 2006; 91(1): 149 - 152. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Liantonio, M. Pusch, A. Picollo, P. Guida, A. De Luca, S. Pierno, G. Fracchiolla, F. Loiodice, P. Tortorella, and D. C. Camerino Investigations of Pharmacologic Properties of the Renal CLC-K1 Chloride Channel Co-expressed with Barttin by the Use of 2-(p-Chlorophenoxy)Propionic Acid Derivatives and Other Structurally Unrelated Chloride Channels Blockers J. Am. Soc. Nephrol., January 1, 2004; 15(1): 13 - 20. [Abstract] [Full Text] [PDF] |
||||